Technical Analysis for OCUL - Ocular Therapeutix, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 6.21 | 0.64% | 0.04 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.64% | |
| Narrow Range Bar | Range Contraction | 0.64% | |
| Weak + Overbought | Other | 0.64% | |
| Inside Day | Range Contraction | 0.64% | |
| Wide Bands | Range Expansion | 0.64% | |
| Weak, Overbought and Reversal Signs | Reversal | 0.64% | |
| Overbought Stochastic | Strength | 0.64% | |
| Weak + Overbought | Other | -0.96% | |
| Wide Bands | Range Expansion | -0.96% | |
| Overbought Stochastic | Strength | -0.96% |
| Alert | Time |
|---|---|
| Up 1% | 7 minutes ago |
| Down 1% | 44 minutes ago |
| Possible NR7 | 3 days ago |
| Possible Inside Day | 3 days ago |
| Down 3% | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/06/2024
Ocular Therapeutix, Inc. Description
Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Eye Inflammation Hypertension Clinical Trial Sealant Glaucoma Platform Technology Eye Diseases Cataracts Incision Treatment Of Glaucoma Allergic Conjunctivitis Cataract Surgery Cornea Allergology Incisions Ocular Hypertension Post Surgical Ocular Inflammation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.31 |
| 52 Week Low | 1.995 |
| Average Volume | 2,641,745 |
| 200-Day Moving Average | 5.01 |
| 50-Day Moving Average | 7.40 |
| 20-Day Moving Average | 5.48 |
| 10-Day Moving Average | 5.94 |
| Average True Range | 0.54 |
| RSI (14) | 48.98 |
| ADX | 21.89 |
| +DI | 23.00 |
| -DI | 27.17 |
| Chandelier Exit (Long, 3 ATRs) | 6.00 |
| Chandelier Exit (Short, 3 ATRs) | 5.67 |
| Upper Bollinger Bands | 6.73 |
| Lower Bollinger Band | 4.24 |
| Percent B (%b) | 0.78 |
| BandWidth | 45.46 |
| MACD Line | -0.26 |
| MACD Signal Line | -0.46 |
| MACD Histogram | 0.2073 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.49 | ||||
| Resistance 3 (R3) | 6.48 | 6.37 | 6.43 | ||
| Resistance 2 (R2) | 6.37 | 6.29 | 6.37 | 6.41 | |
| Resistance 1 (R1) | 6.27 | 6.24 | 6.22 | 6.28 | 6.40 |
| Pivot Point | 6.16 | 6.16 | 6.13 | 6.16 | 6.16 |
| Support 1 (S1) | 6.06 | 6.08 | 6.01 | 6.07 | 5.94 |
| Support 2 (S2) | 5.95 | 6.03 | 5.95 | 5.93 | |
| Support 3 (S3) | 5.85 | 5.95 | 5.91 | ||
| Support 4 (S4) | 5.86 |
